Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

36.37
-1.6300-4.29%
Post-market: 36.01-0.3600-0.99%19:30 EDT
Volume:580.26K
Turnover:21.30M
Market Cap:2.54B
PE:-12.15
High:38.20
Open:38.09
Low:36.08
Close:38.00
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:0.47
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:7.36
PE(LYR):-10.43

Loading ...

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)

TIPRANKS
·
May 10

BRIEF-Pharvaris Announces Pricing Of $115 Million Underwritten Offering Of Ordinary Shares

Reuters
·
May 08

Pharvaris prices $115 million follow-on offering at $29.68 per share

Reuters
·
May 08

Pharvaris Nv: Pricing of an Underwritten Offering of 3,874,664 of Its Ordinary Shares at a Price of $29.68 per Share

THOMSON REUTERS
·
May 08

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

GlobeNewswire
·
May 08

Pharvaris CMO Lu Peng disposes of shares worth $427,111.81

Reuters
·
May 06

Pharvaris Chief Early Development Anne Lesage disposes of shares worth $1.32 million

Reuters
·
May 02

Pharvaris (PHVS) Valuation Check After Conference Data Support For Deucrictibant Combination Regimen

Simply Wall St.
·
Apr 28

Top Pharvaris Executive Executes Notable Insider Stock Sale

TIPRANKS
·
Apr 25

Pharvaris director Johannes Schikan disposes 7,100 shares for $213,678.70

Reuters
·
Apr 25

Pharvaris Chief Early Development Anne Lesage disposes of USD 225,511 common shares

Reuters
·
Apr 25

Pharvaris Chief Medical Officer Lu Peng disposes of common shares worth $213,411

Reuters
·
Apr 24

Is Evidence Backing Dual Deucrictibant Use Altering The Investment Case For Pharvaris (PHVS)?

Simply Wall St.
·
Apr 21

Pharvaris presents data from deucrictibant IR capsule and XR tablet study

TIPRANKS
·
Apr 20

Pharvaris data support combining deucrictibant XR prophylaxis with IR dosing for breakthrough attacks

Reuters
·
Apr 20

Pharvaris price target raised to $52 from $48 at JonesResearch

TIPRANKS
·
Apr 16

Pharvaris Initiated at Outperform by Wolfe Research

Dow Jones
·
Apr 10

Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)

TIPRANKS
·
Apr 08

Pharvaris Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 07

Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says

MT Newswires Live
·
Apr 06